Asset

VS-4718

Verastem Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02215629phase1withdrawn2016-09-01Verastem, Inc.Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
NCT01849744phase1terminated2013-06-012017-04-01Verastem, Inc.Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)